Review
Published · Updated · 2 min read
Ivermectin for scabies in young children: preliminary efficacy and safety data
What it means for practice
Preliminary data on ivermectin for scabies in young children are encouraging, but this report does not establish a change in regulatory restrictions or provide enough information to select a treatment regimen.
Summary
A Pédiatrie Pratique report based on an ESPID presentation discusses ivermectin for scabies in young children. The accessible excerpt states that the drug is not authorised for children weighing less than 15 kg or measuring less than 90 cm because evidence of safety in this population is lacking. The jurisdiction of these restrictions is not specified.
According to the editor-supplied summary, a phase 2 study in Laos reported a scabies cure rate of 91% in young children, with no adverse events in 93% of cases. The available materials do not provide the sample size, exact participant ages, cure criteria or follow-up duration.
The supplied summary also reports the development of age-based dosing strategies that achieved drug exposure similar to that in older children. Specific doses and regimens are not provided. Further studies are planned to assess safety and efficacy in infants and compare oral and topical formulations.
The supplied summary presents ivermectin as a potential treatment option in endemic settings, pending the development of suitable formulations for infants. Neither the full report nor the primary study publication is available in the supplied material, preventing assessment of the methods and reliability of the results.
Source
-
ESPID | Gale : nouvelles données rassurantes sur l’ivermectine chez le jeune enfant. Pédiatrie Pratique.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
